Literature DB >> 31450229

Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200-499 mg/dL) Are Significant Predictors of Hospitalization for New-Onset Kidney Disease: A Real-World Analysis of High-Risk Statin-Treated Patients.

Peter P Toth1,2, Sephy Philip3, Michael Hull4, Craig Granowitz3.   

Abstract

BACKGROUND: Dyslipidemia in kidney disease (KD) involves increased levels of triglycerides (TG) and TG-rich lipoproteins, with only minor changes in low-density lipoprotein cholesterol. The increasing prevalence of diabetic KD and the shared atherogenic lipid profile between KD and diabetes underscore the importance of understanding dyslipidemia in these patients. Previous studies suggest an association between elevated TG and new-onset KD. Additional data are needed to better define the relationship between hypertriglyceridemia and new-onset KD.
OBJECTIVE: To evaluate the real-world impact of elevated and high TG on risk of KD in high-risk statin-treated patients.
METHODS: This retrospective administrative claims analysis of the Optum Research Database included statin-treated patients (age ≥45 years) with diabetes and/or atherosclerotic cardiovascular disease who were followed for ≥6 months. Cohorts included patients with elevated TG (≥150 mg/dL; n = 27,471) or high TG (200-499 mg/dL; subgroup of elevated TG cohort; n = 13,411), and a comparator cohort (TG <150 mg/dL and high-density lipoprotein cholesterol >40 mg/dL; n = 32,506). The probability of hospitalization for new-onset KD was calculated post hoc from multivariate analyses controlled for patient characteristics and comorbidities using a Cox proportional hazards model.
RESULTS: The rate of hospitalization for new-onset KD was 31% higher in the elevated-TG cohort (hazard ratio [HR], 1.311; 95% confidence interval [CI], 1.228-1.401; p < 0.001) and 45% higher in the high-TG cohort (HR, 1.451; 95% CI, 1.339-1.572; p < 0.001) compared with the respective comparator cohorts.
CONCLUSIONS: In a real-world analysis of statin-treated patients with high cardiovascular risk, both elevated TG (≥150 mg/dL) and high TG (200-499 mg/dL) were significant predictors of hospitalization for new-onset KD, identifying hypertriglyceridemia as a potential KD risk factor. The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Cardiovascular disease; Diabetes; Hospitalization; Kidney disease; Triglycerides

Mesh:

Substances:

Year:  2019        PMID: 31450229     DOI: 10.1159/000502511

Source DB:  PubMed          Journal:  Cardiorenal Med        ISSN: 1664-5502            Impact factor:   2.041


  5 in total

1.  Poor Control of Plasma Triglycerides Is Associated with Early Decline of Estimated Glomerular Filtration Rates in New-Onset Type 2 Diabetes in China: Results from a 3-Year Follow-Up Study.

Authors:  Chuan Wang; Lingshu Wang; Kai Liang; Fei Yan; Xinguo Hou; Fuqiang Liu; Li Chen
Journal:  J Diabetes Res       Date:  2020-09-28       Impact factor: 4.011

2.  Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy.

Authors:  Bingman Liu; Liangyu Zhao; Qingqing Yang; Dongqing Zha; Xiaoyun Si
Journal:  Int Urol Nephrol       Date:  2021-04-24       Impact factor: 2.370

3.  Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007-2014.

Authors:  Wenjun Fan; Sephy Philip; Craig Granowitz; Peter P Toth; Nathan D Wong
Journal:  Cardiol Ther       Date:  2020-04-23

4.  Acculturation and Cardiometabolic Abnormalities Among Chinese and Korean Americans.

Authors:  Brittany N Morey; Soomin Ryu; Yuxi Shi; Hye Won Park; Sunmin Lee
Journal:  J Racial Ethn Health Disparities       Date:  2022-06-15

5.  Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity.

Authors:  Borja Lanzon; Marina Martin-Taboada; Victor Castro-Alves; Rocio Vila-Bedmar; Ignacio González de Pablos; Daniel Duberg; Pilar Gomez; Elias Rodriguez; Matej Orešič; Tuulia Hyötyläinen; Enrique Morales; Francisco J Ruperez; Gema Medina-Gomez
Journal:  Metabolites       Date:  2021-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.